Stockreport

Stealth Bio launches clinical development of SBT-272 [Seeking Alpha]

Stealth BioTherapeutics Corp. - American Depositary Shares  (MITO) 
PDF Stealth BioTherapeutics (NASDAQ: MITO initiates SBT-272 is a peptidomimetic that the company is developing for neurodegenerative diseases involving mitochondrial dysfunc [Read more]